Wegovy (Obesity Treatment) - Symptoms, Causes, Treatment & Prevention

Overview

Wegovy® (semaglutide injection) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) in June 2021 for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) who have at least one weight‑related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Wegovy is a glucagon‑like peptide‑1 (GLP‑1) receptor agonist that mimics a naturally occurring hormone that helps regulate appetite and blood glucose.

Obesity affects more than 42 % of U.S. adults (≈ 106 million people) and is a leading cause of preventable morbidity worldwide, according to the Centers for Disease Control and Prevention (CDC) ¹. While lifestyle modification remains first‑line, many individuals need pharmacologic support to achieve and maintain clinically meaningful weight loss (≥ 5 % of body weight). Wegovy is currently the most effective FDA‑approved obesity medication, producing an average 15 %–20 % weight reduction in clinical trials ².

Symptoms

Obesity itself is defined by excess body fat rather than a classic “symptom” set, but patients often present with a constellation of signs and related health problems. When a clinician considers Wegovy, they typically evaluate the following:

Physical Findings

• Elevated Body Mass Index (BMI): ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² with comorbidities.
• Increased waist circumference: > 102 cm (men) or > 88 cm (women) indicating central adiposity.
• Skin changes: Acanthosis nigricans, striae, or intertriginous fungal infections.

Metabolic and Cardiovascular Signs

• Insulin resistance or type 2 diabetes (elevated fasting glucose, HbA1c ≥ 6.5 %).
• Hypertension (BP ≥ 130/80 mmHg).
• Dyslipidemia – high triglycerides, low HDL‑C.
• Obstructive sleep apnea symptoms (snoring, daytime fatigue).

Gastro‑intestinal & Hormonal Symptoms

• Early satiety, reduced appetite (often an expected effect of GLP‑1 therapy).
• Nausea, vomiting, or constipation—common early side‑effects of Wegovy.
• Fatigue or low energy due to rapid weight loss.

Psychosocial Manifestations

• Depressed mood or anxiety related to body image.
• Reduced physical activity because of joint pain or limited mobility.

Causes and Risk Factors

Obesity is a multifactorial disease; Wegovy does not treat a single “cause” but addresses the underlying neuro‑hormonal dysregulation that drives excess food intake.

Primary Drivers

• Genetic predisposition: > 40 % of BMI variation is heritable; several single‑gene mutations (e.g., MC4R) cause severe early‑onset obesity.
• Energy imbalance: Chronic caloric excess relative to expenditure.
• Hormonal factors: Leptin resistance, altered ghrelin, and impaired GLP‑1 signaling.
• Environmental influences: Easy access to high‑calorie foods, sedentary occupations, and limited safe spaces for exercise.

Risk Populations

• Adults with BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with comorbidities).
• Individuals with a family history of obesity or type 2 diabetes.
• People on certain medications (e.g., antipsychotics, corticosteroids, some antidepressants).
• Pregnant or postpartum women (though Wegovy is not approved during pregnancy).
• Certain ethnic groups (e.g., Hispanic, African American) have higher prevalence of obesity.

Diagnosis

Before prescribing Wegovy, clinicians perform a structured assessment to confirm obesity, evaluate comorbidities, and rule out contraindications.

Clinical Evaluation

• History & Physical Exam: Detailed dietary, activity, and psychosocial history; measurement of weight, height, BMI, and waist circumference.
• Laboratory Tests:
  • Fasting glucose or HbA1c.
  • Lipid panel.
  • Liver function tests (ALT, AST) – to screen for non‑alcoholic fatty liver disease.
  • Renal function (eGFR) – dose adjustment may be needed for eGFR < 30 mL/min/1.73 m².
• Imaging (if indicated): Ultrasound or MRI for fatty liver, echocardiogram for cardiac assessment in severe cases.

Diagnostic Criteria for Wegovy Use

1. BMI ≥ 30 kg/m² OR BMI ≥ 27 kg/m² with at least one weight‑related comorbidity.
2. Documented attempt at ≥ 3 months of lifestyle modification (diet, physical activity, behavioral therapy).
3. No contraindications (e.g., personal/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disease).

Treatment Options

Wegovy is part of a broader, multimodal obesity‑treatment framework.

Pharmacologic Therapy

• Wegovy (semaglutide) 2.4 mg subcutaneous injection weekly: Initiated at 0.25 mg and titrated over 16 weeks to the target dose to improve tolerability.
• Other FDA‑approved agents (for context):
  • Orlistat – gastrointestinal fat‑absorption inhibitor.
  • Phentermine‑topiramate, naltrexone‑bupropion, and liraglutide (3 mg) – alternative GLP‑1 analog for patients who cannot tolerate Wegovy.

Procedural Options

• Bariatric surgery: Roux‑en‑Y gastric bypass, sleeve gastrectomy, or adjustable gastric banding for BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² with comorbidities, when medication alone is insufficient.
• Endoscopic interventions: Intragastric balloons or endoscopic sleeve gastroplasty as intermediate options.

Lifestyle Modification (Cornerstone)

• Nutrition: Calorie‑controlled, nutrient‑dense diet (e.g., Mediterranean, DASH). Aim for a 500–750 kcal/day deficit.
• Physical Activity: ≥ 150 min/week of moderate‑intensity aerobic activity plus 2–3 resistance‑training sessions.
• Behavioral Therapy: Cognitive‑behavioral strategies, mindful eating, and regular self‑monitoring.

Living with Wegovy (Obesity Treatment)

Success on Wegovy hinges on integration of medication with sustainable habits.

Administration Tips

• Inject once weekly on the same day, preferably at the same time.
• Rotate injection sites (abdomen, thigh, upper arm) to reduce lipodystrophy.
• Store pens in the refrigerator (2–8 °C) before use; after first use, they may be kept at room temperature for up to 30 days.

Managing Common Side Effects

• Nausea: Take the dose with a small amount of food, avoid high‑fat meals, and consider ginger tea.
• Constipation: Increase fiber (fruits, vegetables, whole grains) and fluid intake; consider a mild stool softener if needed.
• Vomiting or severe abdominal pain: Contact your healthcare provider—may indicate gallbladder disease or pancreatitis.

Monitoring Progress

• Weigh yourself once weekly; aim for a steady 0.5–1 kg loss per week.
• Schedule follow‑up visits every 12 weeks during titration, then every 6 months for maintenance.
• Re‑assess labs (glucose, lipids, liver enzymes) at baseline and annually.

Psychosocial Support

• Enroll in a structured weight‑management program or support group.
• Consider counseling for body‑image issues or depression.
• Involve family members in meal planning and activity routines.

Prevention

While Wegovy treats existing obesity, primary prevention reduces the need for pharmacotherapy.

• Balanced Diet: Emphasize whole foods, limit sugary beverages and processed snacks.
• Regular Physical Activity: Incorporate walking, cycling, or sports into daily life.
• Sleep Hygiene: Aim for 7–9 hours per night; inadequate sleep disrupts leptin and ghrelin.
• Stress Management: Chronic stress raises cortisol, promoting visceral fat accumulation.
• Early Screening: Routine BMI measurement in primary care; intervene when BMI > 25 kg/m².

Complications

If severe obesity remains untreated, a cascade of health problems can develop.

Metabolic Complications

• Type 2 diabetes mellitus – risk increases 3‑fold for BMI ≥ 35 kg/m².
• Hypertension and dyslipidemia – major contributors to atherosclerotic cardiovascular disease (ASCVD).
• Non‑alcoholic fatty liver disease (NAFLD) that can progress to cirrhosis.

Cardiovascular Outcomes

• Coronary artery disease, heart failure, and stroke – obesity adds ~ 20 % excess risk for each.

Respiratory & Orthopedic Issues

• Obstructive sleep apnea, obesity hypoventilation syndrome.
• Osteoarthritis of weight‑bearing joints, leading to reduced mobility.

Other Risks

• Gallbladder disease (gallstones), especially during rapid weight loss.
• Certain cancers (breast, colon, endometrial) have a proven link with excess adiposity.
• Psychological distress, reduced quality of life, and social stigma.

When to Seek Emergency Care

---

**References**

1. CDC. Adult Obesity Prevalence. 2023. https://www.cdc.gov/obesity/data/adult.html
2. Wilding JPH, et al. “Once‑Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021;384:989‑1002. doi:10.1056/NEJMoa2032183
3. Mayo Clinic. “Obesity.” 2024. https://www.mayoclinic.org/diseases-conditions/obesity
4. American Heart Association. “Obesity and Cardiovascular Disease.” 2022. https://www.heart.org/en/health-topics/obesity
5. FDA. “Wegovy (semaglutide) Injection, for Subcutaneous Use.” 2024. https://www.fda.gov/drugs/wegovy
6. Cleveland Clinic. “Weight‑Loss Medications.” 2024. https://my.clevelandclinic.org/health/drugs/21031-weight-loss-medications